Impact of the frequency of plasma HIV-1 RNA monitoring on the outcome of antiretroviral therapy

Current HIV Research

Volumn 9, Issue 2, 2011, Pages 82-87

  Chaiwarith, Romanee ^a   Praparattanapan, Jutarat ^a   Nuntachit, Nontakan ^a   Kotarathitithum, Wilai ^a   Sirisanthana, Thira ^a   Supparatpinyo, Khuanchai ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Antiretroviral therapy; Outcome; Plasma HIV 1 RNA monitoring

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CREATININE; EFAVIRENZ; GPO VIR; HEMOGLOBIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONHUMAN; PATIENT COMPLIANCE; PREDICTION; RASH; RETROSPECTIVE STUDY; RNA ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; VIRUS MUTATION;

EID: 79953320243     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016211795569131     Document Type: Article

References (16)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Cited 2011 January 24].
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-333.
3. Sungkanuparph S, Techasathit W, Utaipiboon C, et al. Thai National Guidelines for Antiretroviral Therapy in HIV-1 Infected Adults and Adolescents 2010. Asian Biomedicine; 4: 515-528.
4. The World Health Organization; antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach 2006 revision. Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf [Cited 2010 January 12].
5. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis 2001; 33: 700-705.
6. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37: 1112-1118.
7. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. Aids 2008; 22: 2097-2106.
8. Chaiwarith R, Salee P, Kotarathitithum W, Sirisanthana T, Supparatpinyo K. Long-term CD4 cell count recovery among Thai naive HIV-infected patients initiating HAART at low CD4 cell count. Curr HIV Res 2009; 7: 340-345.
9. Maneesriwongul WL, Tulathong S, Fennie KP, Williams AB. Adherence to antiretroviral medication among HIV-positive patients in Thailand. J Acquir Immune Defic Syndr 2006; 43 Suppl 1: S119-S122.
10. Land S, Cunningham P, Zhou J, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods 2009; 159: 185-193.
11. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. Aids 1999; 13: 797-804.
12. Guidelines for Clinical Management and Treatment of HIV Infected Adults in Europe. The European AIDS Clinical Society (EACS). November, 2009; 1-23. Available from http://www.euro peanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_In fected_Adults.pdf. [Cited 2011 January 24].
13. Kozal MJ, Hullsiek KH, Macarthur RD, et al. The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007; 8: 357-370.
14. Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis 2004; 190: 1947-1956.
15. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials 2007; 8: 282-292.
16. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146: 564-573.